²²⁵Ac-FPI-2265 (²²⁵Ac-PSMA-I&T) is another Alpha emitter analogue of the marketed ¹⁷⁷Lu-Vipivotide tetraxetan (PSMA-617) and the ²²⁵Ac-labeled analogue of ¹⁷⁷Lu-PSMA-I&T for the treatment of metastasized castration resistant prostate cancer (mCRPC) patients. The running TATCIST trial is designed to evaluate patients with mCRPC with progressive disease, including patients who are naïve to PSMA targeted radiopharmaceuticals and those who have been pre-treated with ¹⁷⁷Lu-based PSMA radiopharmaceuticals.

Target/Mechanism: PSMA

Carrier/Ligand: PSMA-I&T

Radiation Type: Alpha particle (α)